IndustryMarch 2026
Big Pharma's Shift: Why Sanofi's Recent Acquisitions Validate AI-Driven VHH Platforms
Sanofi's strategic acquisitions of single-domain antibody platforms signal a major industry pivot toward VHH-based therapeutics, driven by their superior tissue penetration and manufacturing simplicity.
JFInnova Perspective
JFInnova's fully computational VHH design pipeline — from target discovery to ESM-2 evolution — represents the next generation of this approach, built in Spain with zero wet-lab dependency at design phase.
References
1
Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years
Journal of Nanobiotechnology · 2024
Sanofi VHH acquisition AI